Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — SNRIs and NRIs

Psych CASC / OSCE · Psychopharmacology — SNRIs and NRIs

Starting venlafaxine after SSRI — dual action, BP and discontinuation (CASC)

CASC-style communication station: explain SNRI rationale after SSRI, honest dual-action dose language, BP monitoring, sexual side-effects, discontinuation vs addiction framing, safety-netting and follow-up.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 36-year-old accountant with moderate-severe unipolar MDD attends with her partner. Escitalopram 20 mg for 10 weeks helped anxiety slightly but mood remains low (PHQ-9 16). No bipolar history. She read online that SNRIs are 'stronger dual antidepressants' and also that venlafaxine causes 'horrible addiction withdrawals' and 'heart damage'. BP today 122/76. She wants a clear plan.

Station instructions (candidate)

You have 7 minutes. Speak with the patient (and partner if engaged). Explain why a change from escitalopram is reasonable, what an SNRI is in plain language without overselling “always stronger dual action,” propose a venlafaxine XR start and review plan including blood pressure checks, address “addiction/withdrawal” fears accurately, mention sexual side-effects, and safety-net for early worsening mood or rare dangerous combinations. Do not guarantee remission. Do not dismiss online fears — reframe with evidence.[1][2][4][7]

Marking domains

Empathy and agenda setting; accurate plain-language mechanism (serotonin and, at higher doses, noradrenaline systems); STAR*D-style equipoise that venlafaxine is one good switch option not the only magic drug; dose and titration clarity; BP monitoring; discontinuation vs addiction distinction; sexual side-effect honesty; crisis and early-review plan; partner involvement; no MAOI improvisation.[1][3][4][5][8]

Model communication map

  1. Open: thank them; summarise incomplete response on an adequate escitalopram trial; check what “dual” and “withdrawal” mean to her.[7]
  2. Why change: many people need a second step; large sequential-care evidence supports switching after SSRI non-remission to options including venlafaxine XR, with similar average outcomes to other switches — we individualise.[1]
  3. What SNRI means: medicines that act on serotonin and noradrenaline pathways; with venlafaxine the noradrenaline part is more at higher doses — so we start carefully and only increase if needed, rather than promising instant dual power on day one.[2]
  4. Plan example: cross-taper off escitalopram while starting venlafaxine XR 75 mg (or 37.5 mg first if she is activation-sensitive), review in 1–2 weeks, consider increase toward 150–225 mg only if tolerated and still symptomatic; BP check each step.[3][7]
  5. “Heart damage” talk: can raise blood pressure in some people, more as dose rises — that is why we measure BP, not because everyone gets heart attacks; report severe headache, chest pain or very high home readings.[3]
  6. “Addiction” talk: stopping suddenly can cause short-lived discontinuation symptoms (dizziness, electric-shock feelings, flu-like) because the medicine leaves the system quickly — that is not the same as opioid addiction; we will taper when stopping.[4]
  7. Sexual function: many antidepressants can affect sex drive, arousal or orgasm — we will ask at reviews and can adjust plan rather than suffer in silence.[5]
  8. Safety: more contact early if mood worsens, agitation or suicidal thoughts; list all other medicines/supplements (avoid MAOI combinations and random online stacks).[8][7]
  9. Close: written plan, questions, crisis contacts; optional psychology alongside medicine.[6][7]

Common fails

  • Promising venlafaxine is always stronger than every SSRI for every person.[6]
  • Ignoring BP or sexual side-effects.[3][5]
  • Calling discontinuation “proof of addiction.”[4]
  • Starting 225–375 mg on day one without titration talk.[2]
  • Dismissing the partner or online fears without accurate reframing.

References

  1. [1]Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med, 2006.PMID 16554525
  2. [2]Blier P, Saint-André E, Hébert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers Int J Neuropsychopharmacol, 2007.PMID 16690005
  3. [3]Thase ME Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients J Clin Psychiatry, 1998.PMID 9818630
  4. [4]Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research J Clin Psychiatry, 2006.PMID 16683860
  5. [5]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
  6. [6]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
  7. [7]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
  8. [8]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664